1. 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. (September 2015) Authors: Lin, K.; Sun, J.; Maloney, L.; Goble, S.; Oza, A.; Coleman, R.; Scott, C.; Robillard, L.; Mann, E.; Isaacson, J.; Harding, T.; Giordano, H.; Rolfe, L.; McNeish, I.; Swisher, E.; Yelensky, R.; Allen, A.; Raponi, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗